Skip to main content

Table 1 Baseline (first visit) clinical characteristics of the patients

From: The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients

Variables No. (%)
Age in years, mean ± SD 47.6 ± 10.5
FH of cancer 3 (4.1)
Type of receptors
 Progesterone receptor (PR) positive 48 (64.9)
 Estrogen receptors (ER) positive 22 (29.8)
 HER receptor positive 61 (82.5)
TNM staginga
T (tumor size)  
  T1 7 (9.5)
  T2 46 (62.2)
  T3 21 (28.4)
N (lymph node spread)  
  N0 18 (24.3)
  N1 56 (75.7)
M (blood spread)  
  M0 74 (100)
Grade of breast cancer
 IDC-IIb 71 (95.9)
 IDC-IIIb 3 (4.1)
Site of breast cancer
 Right 32 (43.2)
 Left 41 (55.4)
 Bilateral 1 (1.35)
Surgery
 Pre chemotherapy 54 (73.0)
 Post chemotherapy 20(27.1)
Planned chemotherapeutic agents
 A (doxorubicin) 43 (58.1)
 E (epirubicine) 27 (36.5)
 T (docetaxel) 4 (5.4)
 C (cyclophosphamide) 73 (98.6)
  1. DM diabetes mellitus, HTN hypertension, IDC invasive ductal carcinoma, FH family history, T tumor, N lymph node, M metastasis
  2. aTNM staging where T refers to the tumor size (T1; size <2 cm, T2; size 2–5 cm, T3; size >5 cm), N refers to lymph node affection (N0; no cancer cells in the nearby lymph nodes, N1; some cancer cells are found in the axillary lymph nodes, but the nodes are not stuck to the surrounding), and M refers to blood metastases (M0; no metastases)
  3. bIDC, invasive ductal carcinoma (grade II is a moderately differentiated while grade III is a poorly differentiated IDC)